33 results about "RUNX1" patented technology

The invention discloses a combined genome for evaluating prognosis of clear cell renal cell carcinoma (ccRCC) and application of the combined genome, relates to the technical field of medical biological detection, and provides novel application of the combined genome of ADAMTS9, C1S, DPYSL3, H2AFX, MINA, PLOD2, RUNX1, SLC19A1, TPX2 and TRIB3, particularly application in preparation of a ccRCC prognosis evaluation reagent or kit. The genome is derived from a molecular marker significantly correlated with a ccRCC metastasis way, and the discovery of the genome model provides a new strategy for predicting the ccRCC recurrent risk and the long-term survival condition of a patient after operation, plays important roles in judging the prognosis of the ccRCC patient, can evaluate the risk level of tumor progression or death of the patient after ccRCC operation, contributes to guiding a clinician to perform an individualized precise therapeutic strategy, can increase the postoperative survivalrate of the patient, and has important guide significance postoperative follow-up monitoring and sequential therapy management of the ccRCC patient.

The invention belongs to the technical field of RUNX1 gene splitting and copy number increase detection and provides a RUNX1 gene splitting and copy number increase detection kit and a preparation method thereof. A probe for detecting gene splitting is designed according to the characteristic of gene splitting. The preparation method is characterized by selecting RP11-177L11BAC and RP11-77I17BAC clones and respectively marking RP11-177L11BAC and RP11-77I17BAC with green and red to serve as probe sequences, carrying out FISH (fluorescence in situ hybridization) on the sequences and a cell to be detected after purifying, precipitating and dissolving the sequences, and carrying out fluorescent microscopic observation on cell signals, wherein normal somatic cells have two yellow signals; once genes are split, one red signal, one green signal and one yellow signal appear, and the corresponding quantity of yellow signals appear when the copy number increases. By adopting the kit and the preparation method, the method for accurately detecting gene splitting is created, the defects of the existing gene splitting detection means are overcome, the RUNX1 gene splitting and copy number increase incidents are rapidly and accurately detected and identified, and partner genes fused with an RUNX1 gene are determined in combination with subsequent RACE (rapid amplification of cDNA ends) detection.

A kit for detecting esophagus cancer related risky genes is disclosed. The kit includes: specific primer pairs, specific fluorescence probe pairs, common components for fluorogenic quantitative PCR detection; and the like, wherein the specific primer pairs and the specific fluorescence probe pairs are used for simultaneously detecting a number rs2274223 SNP site on a PLCE1 gene, a number rs13042395 SNP site on a C20orf54 gene, a number rs2074356 SNP site on a C12orf51 gene, a number rs2014300 SNP site on an RUNX1 gene, a number rs11066015 SNP site on an ACAD10 gene and a number rs10052657 SNP site on a PDE4D gene. The kit evaluates the risk of esophagus cancer for a person through simultaneously detecting single nucleotide polymorphic site genotypes of the PLCE1, the C20orf54, the C12orf51, the RUNX1, the ACAD10 and the PDE4D which are closely related with the esophagus cancer.

The invention discloses a method for screening a miR-181b target gene. The method comprises the following steps: taking a goat ovarian tissue cDNA (complementary Deoxyribonucleic Acid) as a template and carrying out amplification in the presence of Taq DNA polymerase, a buffering environment, Mg<2+> and dNTPs by utilizing a primer RUNX1 under the condition of PCR (Polymerase Chain Reaction), so asto obtain a determined PCR product which is a sequence of a 3' UTR region of an RUNX1 gene; then constructing a dual-luciferase reporting system and detecting the activity of luciferase; primarily identifying the miR-181b target gene; detecting the influences, caused by the fact that miR-181b is detected by adopting an RT-qPCR method, on the level of an RUNX1 gene on mRNA (massager Ribonucleic Acid); detecting the influences, caused by the fact that the miR-181b is detected by adopting a Western blot method, on a protein level of the RUNX1 gene. A combination site with the miR-181b exists inthe RUNX1 3' UTR region; a modern molecular biotechnology is used for verifying a targeting regulation relation of the miR-181b and the target gene RUNX1 and the miR-181b can be used for inhibiting the expression of the RUNX1 gene in the mRNA and protein levels; furthermore, the method confirms that the RUNX1 is a target gent of the miR-181b. The method lays a foundation for further researching influences, caused by the miR-181b, on ovarian development and lambing performance of dairy goats.

The invention provides a kit for combined detection of acute myeloid leukemia. The kit comprises a special linker for DNA library construction, a specific composite primer for detecting gene rearrangement and gene whole exon mutation, and a composite primer for library amplification. The special linker is 8 dimers formed by a linker primer 1 and eight different i5-terminal primers respectively; the types of the gene rearrangement and the gene whole exon mutation are CBFB rearrangement, RUNX1 rearrangement, MLL rearrangement, RARA rearrangement, MECOM rearrangement and TP53 gene whole exon mutation; and the composite primer for library amplification has different i7 terminals. The kit provided by the invention can be used for detecting a plurality of common molecular genetic variations of acute myeloid leukemia at one time, and is simple to operate, short in time and high in detection efficiency.

The invention discloses a method and primers for detecting a fifth exon mutation site of a RUNX1 gene. The method and the primers comprise a forward primer, a reverse primer and a pair of sequencing primers for amplifying the fifth exon mutation site of the RUNX1 gene. The method combines a Touch-down PCR amplification and a Sanger sequencing method, can rapidly detect mutation conditions of the fifth exon mutation site of the RUNX1 gene in an acute myeloid leukemia patient body.

A method for treating acute myeloid leukemia (AML), such as poor risk AML, by administering to a subject in need thereof an effective amount of a mitochondrial activity inhibitor, for example a classA electron transport chain (ETC) complex I inhibitor such as Mubritinib or a pharmaceutically acceptable salt thereof, is disclosed. The AML to be treated may be characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and / or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, normal karyotype (NK), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and / or abnormal chromosome (5 / 7), and / or a high leukemic stem cell (LSC) frequency.

The invention relates to a mixed gene for a detecting fusion gene. A gene sequence of the mixed gene is shown in SEQ ID NO:1. The mixed gene comprises a BCR-ABL fusion gene shown in SEQ ID NO:2, an AML-ETO fusion gene shown in SEQ ID NO:3, a PML-RARA fusion gene shown in SEQ ID NO:4 and an ABL reference gene shown in SEQ ID NO: 5. The invention further relates to standard plasmid containing the mixed gene, and the standard plasmid comprises PUC57 plasmid shown in SEQ ID NO: 6. The invention further relates to a kit containing the standard plasmid and further relates to a preparation method ofthe standard plasmid. The mixed gene has the advantages that the mixed gene can be applied to establishing a double-standard curve which is used for quantitatively detecting BCR-ABL, RUNX1-RUNX1T1 (AML-ETO) and PML-RARA fusion gene in a leukemia related fusion gene in human marrow or a peripheral blood sample; detection efficiency and accuracy are effectively improved, manual operation errors arereduced, and multi-plasmid pollution is prevented from happening; the lowest detection copy number of the standard plasmid is 1*10<0> per ml; operation is simple, pollution is not prone to happening,the detection range is large, and detection cost can be effectively reduced.

The invention relates to a somatic cell nuclear transplantation method and application thereof. According to the method, a single allele is obtained by using a haploid embryonic stem cell system, and meanwhile, one or more donor somatic cells in 26 H3K27me3 related imprinting genes are knocked out for nuclear transplantation. Results show that a single allelic knockout of one or more of Slc38a2, Slc38a4, Sfmbt2, Etv6, Platr4, Gramd1b, Slc38a1, Gab1, Mbnl2, Smoc1, Bmp7, Rbms1, Fam198b, Sh3gl3, Hunk, Jade1, E2f3, Tle3, Runx1, Epas1, Bbx, Enc1, Inhbb, Sox21, Otx2, Rbp2 (e.g., one or more of four of Sfmbt2, Jade1, Gab1 and Smoc1)of the H3K27me3 related imprinting genes, the imprinting expression pattern of the genes tends to be normal. Meanwhile, the somatic cell cloning efficiency can be improved to 14% when the donor somatic cells are used for cloning, and the somatic cell cloning efficiency of a wild type control group is 0. In addition, according to the cloned animal obtained by the method, a large placenta-large fetus phenomenon is corrected.

The invention discloses application of mutant zebra fish in preparation of an animal model of a common variable immunodeficiency disease (CVID). The mutant zebra fish is runx1W84X / W84X mutant zebrafish. It is found for the first time in the invention that runx1 mutation of the zebrafish is associated with B lymphocyte development, the zebrafish runx1W84X / W84X mutant has the symptoms of the CVID similar to humans, and it is proved that the runx1W84X / W84X mutant zebrafish B has a lymphocyte immune response function defect. In addition, the human CVID disease model with B lymphocyte development disorder, IgM and IgZ rearrangement defects and T cell development unaffected or slightly affected is established for the first time. The zebrafish model can become a new carrier for studying the CVIDand drug screening.

The invention relates to the technical field of gene engineering, in particular to a targeting capture probe of a tumor fusion gene and application of the targeting capture probe. By utilizing the probe combination and combining a high-throughput sequencing technology, fusion genes related to transcription levels BCR, ABL1, RUNX1, CBFB, PML, RARA and KMT2A can be detected, the detection rate is high, the sensitivity is high, the detection period is short, the detection cost is low, and the detection sensitivity reaches more than 1%.

The invention discloses a detecting typing kit for a susceptibility gene of esophagus cancer and an application thereof. The detecting typing kit for the susceptibility gene of esophagus cancer can detect three polymorphic loci PED4D, PLCE1 and RUNX1 of an esophagus cancer related gene, so that the genetic factors of an individual in the aspect of esophagus cancer can be known, the relative risk of esophagus cancer can be estimated, and the kit has positive meaning in diagnosing, early treating and intervening esophagus cancer. Meanwhile, the kit also can assist diagnosis of esophagus cancer, guide reasonable medication, and is helpful for predicating morbid risk of offsprings and the like.

The invention provides a potential antigen obviously related to prognosis of renal clear cell carcinoma, an immune subtype and a construction method and application thereof, and the potential antigen comprises one or more of the following antigen genes: ZAP70, VMP1, TUBB6, TPX2, TOP2A, TMEM74B, TMC8, TGM2, TGFA, TEX11, SPON2, SNX33, SERPINH1, RUNX1, RRM2, RGCC, PTTG1, PTP4A3, PPP1R18, PLAUR, PABPC1L, NCF4, MYBL2, MUC3A, MSC, MGARP, FOXM1, FMNL1, FBXL16, EDN1, DOK3, COL5A3, CDHR5, according to the invention, a new tumor antigen of renal clear cell carcinoma is explored to be suitable for research and development of mRNA vaccine of KIRC; besides, the invention also identifies the immune typing of the KIRC, so that the immune typing is used for predicting the treatment effect of the renal clear cell carcinoma vaccine prepared based on potential antigens significantly related to renal clear cell carcinoma prognosis on renal clear cell carcinoma patients, and a new thought is provided for developing mRNA vaccines of the KIRC and identifying KIRC patients suitable for mRNA vaccination.

The invention discloses a kit for predicting prognosis risk of lung squamous cell carcinoma and application of the kit, and relates to the technical field of gene engineering and oncology. The kit candetect sequence information of a target area, and the target areas are selected from areas 1-127 in a table 1 and are specific areas located in ARID1A, SLC43A2, ANKS1A, CHD2, RPTOR, OR7A5 and RUNX1 genes. By detecting the sequence information of the target areas, prognostic risks of lung squamous cell carcinoma tumor patients can be effectively and rapidly predicted, compared with other clinicalmarkers, mutation of the target areas have higher specificity, and detection is convenient and rapid.

The invention discloses a method and primers for detecting a third exon mutation site of a RUNX1 gene. Both the primers and the method comprise a forward primer, a reverse primer and a pair of sequencing primers. By adopting a Sanger sequencing method and by utilizing the pair of sequencing primers, the method and the primer can be used for rapidly detecting mutation conditions of the third exon mutation site of the RUNX1 gene in an acute myeloid leukemia patient body.

A method of diagnosing a pathology resulting from a runt-related transcription factor 1 (RUNX1) inactivation in a subject, which includes the step of i) determining the platelets' myosin non-muscle heavy chain 10 (MYH10) expression level in a biological sample from the subject, and wherein a detectable platelets' MYH10 expression level is indicative of a pathology resulting from a runt-related transcription factor 1 (RUNX1) inactivation, and to a kit for diagnosing a pathology resulting from a runt-related transcription factor 1 (RUNX1) inactivation in a subject including i) at least one antibody for determining the platelet MYH10 expression level in a biological sample from the subject, which can be used in a such a method.

The present invention discloses methods of identifying candidate compounds for modulating the activity of Runx2 or Runx1 through inhibition by ERα or AR in a cell, and using such compounds for treating bone diseases and cancer. Also disclosed are isolated polypeptides having fragments of a Runx2 protein or an AR protein involved in Runx2-ERα, Runx2-AR, or Runx1-AR interactions, their coding nucleic acids, and utilities of these polypeptides in modulating the activity of Runx2 or Runx1 through inhibition by ERα or AR in a cell.

The present invention relates to a kind of mixed gene that is used for detecting fusion gene, and its gene sequence is as shown in SEQ ID NO:1, comprises the BCR-ABL fusion gene of SEQ ID NO:2, the AML-ETO fusion gene of SEQ ID NO:3 , the PML-RARA fusion gene of SEQ ID NO:4 and the ABL internal reference gene of SEQ ID NO:5; also relate to the standard plasmid that contains mixed gene, comprise the PUC57 plasmid of SEQ ID NO:6; Also relate to a kind of standard plasmid that contains The kit; also relates to a preparation method of a standard plasmid. Its advantage is, can be used for in the leukemia-associated fusion gene in quantitative detection people's bone marrow or peripheral blood sample BCR-ABL, RUNX1-RUNX1T1 (AML-ETO) and PML-RARA fusion gene double standard curve establishment; Effectively improve Improve detection efficiency and accuracy, reduce human error, and avoid multi-plasmid contamination; the minimum detection copy number of standard plasmids is 1*10 0 pcs / ml; easy to operate, not easy to pollute, large detection range, can effectively reduce detection cost.

The invention relates to an oligonucleotide, method and kit for detecting ETV6-RUNX1 fusion gene in a sample. The kit mainly comprises an upstream primer ETV6-F, a downstream primer RUNX1-R and a probe ETV6-Probe for detecting the ETV6-RUNX1 fusion gene, and an upstream primer ABL-F, a downstream primer ABL-R and a probe ABL-Probe for detecting ABI reference gene. The kit is used for detecting thecondition of the ETV6-RUNX1 fusion gene in-vivo acute B lymphocytic leukemia patients, and can conveniently carry out related auxiliary diagnosis and treatment.

The invention belongs to the technical field of RUNX1 gene splitting and copy number increase detection and provides a RUNX1 gene splitting and copy number increase detection kit and a preparation method thereof. A probe for detecting gene splitting is designed according to the characteristic of gene splitting. The preparation method is characterized by selecting RP11-177L11BAC and RP11-77I17BAC clones and respectively marking RP11-177L11BAC and RP11-77I17BAC with green and red to serve as probe sequences, carrying out FISH (fluorescence in situ hybridization) on the sequences and a cell to be detected after purifying, precipitating and dissolving the sequences, and carrying out fluorescent microscopic observation on cell signals, wherein normal somatic cells have two yellow signals; once genes are split, one red signal, one green signal and one yellow signal appear, and the corresponding quantity of yellow signals appear when the copy number increases. By adopting the kit and the preparation method, the method for accurately detecting gene splitting is created, the defects of the existing gene splitting detection means are overcome, the RUNX1 gene splitting and copy number increase incidents are rapidly and accurately detected and identified, and partner genes fused with an RUNX1 gene are determined in combination with subsequent RACE (rapid amplification of cDNA ends) detection.

The invention relates to the technical field of gene engineering, in particular to a method for directional differentiation of induced pluripotent stem cells into lymphoid tissue induced cells. At least one of a transcription factor Runx1, a transcription factor Tcf1, a transcription factor Id2, a transcription factor Rorgamma t, a transcription factor Batf3 and a transcription factor Nfil3 is overexpressed in the induced pluripotent stem cells. The induced pluripotent stem cell line is constructed by utilizing a stem cell technology, so that the construction requirement of transcription factor gene reporter mice of lymphatic progenitor cells in different stages is met, the repeatability of differentiation is improved by stably overexpressing a specific transcription factor combination, and the functional integrity of the lymphatic tissue induced cells obtained by induction is improved.

The invention discloses a method and primers for detecting a fifth exon mutation site of a RUNX1 gene. The method and the primers comprise a forward primer, a reverse primer and a pair of sequencing primers for amplifying the fifth exon mutation site of the RUNX1 gene. The method combines a Touch-down PCR amplification and a Sanger sequencing method, can rapidly detect mutation conditions of the fifth exon mutation site of the RUNX1 gene in an acute myeloid leukemia patient body.

The present invention relates to a novel C-terminal exon of RUNX1 / AML1, its nucleic acid sequence, its peptide and a full length amino acid sequence comprising the novel C-terminal exon. Furthermore, the invention is directed to an antibody against the C-terminal exon of RUNX1 / AML1, a pharmaceutical composition for the treatment of various diseases, among others various tumours and the use of the C-terminal exon for the manufacture of a medicament. The C-terminal exon may also be used for the inhibition of cellular growth and / or induction of apoptosis. Furthermore, the invention relates to a method and a kit for diagnosing a disease, both using the C-terminal exon.

The invention provides a preparation method and application of human hematopoietic progenitor cells with B lineage differentiation potential. The preparation method comprises: introducing three transcription factors RUNX1, HOXA9 and LHX2 into a human pluripotent stem cell induction differentiation system simultaneously or separately The cells of the human pluripotent stem cell induced differentiation system include human pluripotent stem cells, mesoderm cells, hematopoietic endothelial cells or Any one or a combination of at least two of the hematopoietic progenitor cells; the method for inducing differentiation includes a method for inducing differentiation by monolayer culture based on co-culture of stromal cells or a method for inducing differentiation by three-dimensional culture of organoids. The preparation method has good induction and differentiation efficiency, and the prepared cells have good activity and high differentiation ability, and have important application value.

The invention relates to the field of cancer, in particular breast cancer. In particular it relates to the field of immune system directed approaches for tumor reduction and control. Some aspects of the invention relate to vaccines, vaccinations and other means of stimulating an antigen specific immune response against a tumor in individuals. Such vaccines comprise neoantigens resulting from frameshift mutations that bring out-of-frame sequences of the GATA3, CDH1, MAP3K1, RUNX1, and TP53 genes in-frame. Such vaccines are also useful for ‘off the shelf’ use.

This invention relates to compounds that bind to wild-type CBFβ and inhibit CBFβ binding to RUNX proteins. The potent compounds of the invention inhibit this protein-protein interaction at low micromolar concentrations, using allosteric mechanism to achieve inhibition, displace wild-type CBFβ from RUNX1 in cells, change occupancy of RUNX1 on target genes, and alter gene expression of RUNX1 target genes. These inhibitors show clear biological effects consistent with on-target RUNX protein activity. Pharmaceutical compositions containing a compound of the invention and a pharmaceutically acceptable carrier represent a separate embodiment of the invention. Another embodiment of the invention are methods of treating a RUNX-signaling-dependent cancer that expresses wild-type CBFβ in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention. In one embodiment, the cancer is selected from the group consisting of a RUNX-signaling-dependent leukemia that expresses wild-type CBFβ, lung cancer, bladder cancer, ovarian cancer, uterine cancer, endometrial cancer, breast cancer, liver cancer, pancreatic cancer, stomach cancer, cervical cancer, lymphoma, leukemia, acute myeloid leukemia, acute lymphocytic leukemia, salivary gland cancer, bone cancer, brain cancer, colon cancer, rectal cancer, colorectal cancer, kidney cancer, skin cancer, melanoma, squamous cell carcinoma of the tongue, pleomorphic adenoma, hepatocellular carcinoma, pancreatic cancer, squamous cell carcinoma, and / or adenocarcinoma. In another embodiment, the compounds of the invention can be used to treat a leukemia, lung cancer, ovarian cancer, and / or breast cancer.

The invention relates to the field of application of molecular biology, and in particular, relates to an application of an LncRNA marker in detection or evaluation of immune function of lung cancer. LncRNA RUNXOR is found out to have obvious expression difference in blood of patients with lung cancer for the first time. Compared with a control group of normal people, an experimental group of patients with lung cancer has high-expression LncRNA molecular marker RUNXOR, and has the expression level of LncRNA RUNXOR after operation obviously reduced; with the expression of RUNX1, the differentiation and immunosuppressive function of MDSCs are regulated. Based on the finding, LncRNA RUNXOR can be used as a molecular marker for regulating the immune function of lung cancer or a target applied in clinical diagnosis or targeted treatment of lung cancer. Through detection, the LncRNA RUNXOR provided by the method can be applied in products for detection / evaluation of lung cancer immune function, is advantageous to further elucidating the mechanism of occurrence and development of lung cancer, and has important guiding significance for treatment of lung cancer.

The invention discloses a primer pair RUNXF / RUNXR for detecting a gene polymorphism site of RUNX1 rs2268277 by using a PCR (Polymerase Chain Reaction) method, wherein the sequences of the primer pair are as shown in SEQ ID NO.1 and SEQ ID NO.2 respectively. The invention further discloses the application of the primer pair RUNXF / RUNXR in detecting the gene polymorphism site of a biological sample IMPDH1 rs4731447, and a detection kit which is prepared from the primer pair and used for detecting the gene polymorphism site of the RUNX1 rs2268277. By adopting the primer pair and the PCR method of the primer pair disclosed by the invention, the gene type of the gene polymorphism site of the RUNX1 rs2268277 can be confirmed according to amplification electrophoresis results, the treatment effect and the side effect of a purinethol medicine can be predicted, the effectiveness and the security of the purinethol medicine administrated to a patient can be predicted on the basis of gene type analysis, clinical medicine administration can be instructed, and individual treatment on patients can be achieved.